Skip to content

Biohaven BHVN Total Equity

Total Equity at other companies

Eli Lilly logo
Eli LillyLLY
$31.2B+97.9%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.34B+90.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$471.51M+65.0%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$812.77M-22.1%
uniQure logo
uniQureQURE
$149.34M+343%
Roivant Sciences logo
Roivant SciencesROIV
$4.53B-3.4%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's total equity?
Biohaven (BHVN) reported total equity of $129.5M in Q1 2026.
How has Biohaven's total equity changed year-over-year?
Biohaven's total equity decreased by 50.1% year-over-year, from $259.5M to $129.5M.
What is the long-term trend for Biohaven's total equity?
Over 5 years (2020 to 2025), Biohaven's total equity has grown at a 25.4% compound annual growth rate (CAGR), from $16.78M to $52.07M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.